Crossmark Global Holdings Inc. Buys 449 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Crossmark Global Holdings Inc. boosted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 25.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,186 shares of the company’s stock after acquiring an additional 449 shares during the period. Crossmark Global Holdings Inc.’s holdings in Krystal Biotech were worth $398,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in KRYS. Price T Rowe Associates Inc. MD boosted its stake in shares of Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after acquiring an additional 231,255 shares during the period. Dimensional Fund Advisors LP grew its holdings in Krystal Biotech by 1.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after buying an additional 7,537 shares in the last quarter. Hood River Capital Management LLC raised its position in shares of Krystal Biotech by 5.1% during the second quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after buying an additional 25,507 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock worth $35,583,000 after buying an additional 103,928 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Krystal Biotech by 11.4% during the second quarter. Allspring Global Investments Holdings LLC now owns 176,446 shares of the company’s stock worth $32,402,000 after acquiring an additional 18,021 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 3.7 %

Krystal Biotech stock opened at $170.74 on Monday. Krystal Biotech, Inc. has a 12-month low of $96.73 and a 12-month high of $219.34. The firm has a 50-day moving average price of $180.83 and a 200-day moving average price of $181.64. The firm has a market capitalization of $4.91 billion, a PE ratio of 96.46 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.67) earnings per share. As a group, sell-side analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the stock. Stifel Nicolaus boosted their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Citigroup raised their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Chardan Capital upped their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $197.00.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 14.10% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).